Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

p>

achieved.

Financial Highlights

Net sales of Vancocin(R) were $47.7 million for the fourth quarter of 2007 and $203.8 million for the twelve months of 2007 as compared to $38.5 million and $166.6 million in the respective 2006 periods.

Investment in our product pipeline and the Company continued to grow as research and development (R&D) and marketing, general and administrative (MG&A) expenses were $25.2 million and $72.9 million for the fourth quarter and twelve months of 2007, respectively compared to $10.2 million and $43.7 million for the fourth quarter and twelve months of 2006, respectively. These increases were due primarily to our two phase three studies for Camvia and increased personnel to support our clinical pipeline, along with increased marketing, general and administrative expense due to increases in medical education, share-based compensation and legal and consulting costs.

Operating income in the fourth quarter and twelve months ended December 31, 2007 was $19.0 million and $115.8 million, respectively, compared to $25.1 million and $98.8 million in the fourth quarter and twelve months of 2006, respectively. Operating income in the fourth quarter decreased primarily due to higher R&D and MG&A costs discussed above partially offset by the higher net sales. Operating income for the twelve months of 2007 increased due to higher net sales and lower cost of sales, partially offset by the increase in R&D and MG&A expenses.

"2007 represented a period of strong momentum for ViroPharma - clinical momentum, organizational momentum, and operational momentum - as we continue to be driven by our commitment to bring essential therapies to patients with few, if any, treatment options," commented Michel de Rosen, ViroPharma's chief executive officer. "Our 2007 clinical efforts were primarily driven by Camvia, which was granted Orphan Drug designation in both the U.S. and E.U. and gained global momentum through our pivotal ph
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Breast cancer patients treated with lumpectomy followed by ... had bilateral mastectomy, according to a large study ... of Medicine and the Cancer Prevention Institute of ... California women with the disease is the first ... most common surgical interventions: bilateral mastectomy (the removal ...
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... the emergency department within a few days of discharge do ... have lost trust in other parts of the health care ... today in Annals of Emergency Medicine ( "Return ... , "When asked why they did not follow up ... too severe to wait until their scheduled appointment or being ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey ... 2014 during Spinal Cord Injury Awareness Month featuring full band ... Chuck Ligon. Linear Automotive will be there hosting a Hot ... open at 2pm. The car show is Pre 1964 only, ... to the concert. There will be trophies for top 3 ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
Breaking Medicine News(10 mins):Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... As the U.S. immigrant population grows it will be necessary ... have access to health insurance coverage, or who face other ... (ACP) said in a new policy paper released today at ... and Access to Health Care discusses the challenges immigrants face ...
... , THURSDAY, April 7 (HealthDay News) -- After hooking up ... the computer to "read" the thoughts of disabled patients, thereby ... The researchers are hoping the breakthrough will one day lead ... world around them. "We have been fundamentally interested in ...
... NY) For many types of cancer, the original tumor ... a tiny subpopulation of cells from the primary tumor to ... too often kills the patient. Now, researchers at ... have identified two molecules that enable cancer to spread inside ...
... the American Thyroid Association (ATA) on outpatient radioiodine (131I) ... the safety of patients, their families, and the public. ... issue of Thyroid , a peer-reviewed journal published ... ATA recommendations are available free online at www.liebertpub.com/thy ...
... WEDNESDAY, April 6 (HealthDay News) -- Long-term users of the ... a new study. Brain scans showed an approximate 10 ... lower proportion of overall gray matter among long-term ecstasy users, ... who use ecstasy can develop serious memory problems, so a ...
... Virtual reality and other video games can significantly improve ... Michael,s Hospital. Patients who played video games, such ... likely to show improvements in arm motor function compared to ... is a promising and potentially useful alternative to enhance motor ...
Cached Medicine News:Health News:Physicians call for better access to health care for immigrants 2Health News:Physicians call for better access to health care for immigrants 3Health News:Scientists Use Computer to 'Read' Human Thoughts 2Health News:Scientists Use Computer to 'Read' Human Thoughts 3Health News:Molecules identified that help propel cancer metastasis 2Health News:New radiation treatment practice recommendations for thyroid disease 2Health News:Long-Term Ecstasy Users at Risk for Brain Damage, Study Warns 2Health News:Video games effective treatment for stroke patients: study 2
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... , September 2, 2014 Today, ... (NYSE: WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ZTS ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted ...
(Date:9/2/2014)... DUBLIN , Sept. 2, 2014 Actavis ... the U.S. Food and Drug Administration (FDA) has accepted ... an investigational drug for the treatment of diarrhea and ... Irritable Bowel Syndrome (IBS-D).  Actavis, NDA for eluxadoline has ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO "The ...
Breaking Medicine Technology:Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4
... , SAN CLEMENTE, Calif., Nov. 17 Three ... ages of two through 12 are extremely, very, or ... according to a survey conducted by Opinion Research Corporation ... research of natural remedies including Sinupret® for Kids, a ...
... , DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. ... has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers ... which are going out today, cover orders received through ... for our company - actually shipping a product to ...
Cached Medicine Technology:Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
Medicine Products: